Accumulating evidence suggests that dysregulated levels of APP metabolites contribute to FXS pathology (Figure 1), supporting the hypothesis that pharmaceuticals under study for modulation of APP and amyloid-beta in AD may be viable therapeutic strategies for FXS (Westmark et al., 2013; Pasciuto et al., 2015). Here, APP is linked to fragile X syndrome.